Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
Qitong Chen, Dengjie Ouyang, Munawar Anwar, Ning Xie, Shouman Wang, Peizhi Fan, Liyuan Qian, Gannong Chen, Enxiang Zhou, Lei Guo, Xiaowen Gu, Boni Ding, Xiaohong Yang, Liping Liu, Chao Deng, Zhi Xiao, Jing Li, Yunqi Wang, Shan Zeng, Jinhui Hu, Wei Zhou, Bo Qiu, Zhongming Wang, Jie Weng, Mingwen Liu, Yi Li, Tiegang Tang, Jianguo Wang, Hui Zhang, Bin Dai, Wuping Tang, Tao Wu, Maoliang Xiao, Xiantao Li, Hailong Liu, Lai Li, Wenjun Yi, Quchang Ouyang
Abstract
In the original article, the following line in paragraph two of the “Data Collection” sub-section of the “PATIENTS AND METHODS” was incorrect: “Second-line treatment was that given to a patient with recurrence within 12 months of discontinuation of trastuzumab, or recurrence during adjuvant therapy with trastuzumab.”The correct version of this line is as follows: Second-line treatment was that given to a patient with recurrence within 12 months of discontinuation of trastuzumab, or recurrence during adjuvant therapy with trastuzumab, or progression following first-line treatment."In the original article, the second subtitle of the “RESULTS” section was incorrect:“Effeteness of Switching Use of TKIs”The correct version of this subtitle is as follows: “Effectiveness of Switching Use of TKIs”The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.